Historically, diagnosing and managing multiple sclerosis (MS) has been difficult. Research uncovering the immune-mediated mechanisms of MS emergence, relapse, and progression has led to development of biomarkers that are now central to diagnosis and treatment decisions, as well as to the development of immune-targeted disease-modifying therapies (DMTs) that can induce long-term remission. Most DMTs are used in continuous or maintenance/escalation therapy regimens, and disease activity typically recurs when these drugs are discontinued. In contrast, pulsed immune reconstitution therapy (IRT) are administered in short courses and provide durable efficacy beyond the active treatment period. This paradigm shift requires health care providers (HCPs) to stay up to date on the range of available and emerging therapies for MS and current guidance on treatment selection and the role of biomarkers in the management of patients with MS.
In this CME Outfitters Live and OnDemand webcast, animated 3-D models will illustrate the immune processes that contribute to MS pathology and serve as targets for immune-directed therapies. Expert faculty will review clinical data supporting the efficacy and safety of novel and emerging immune-directed therapies as well as the role of biomarkers in assessing disease progression and guiding treatment decisions in patients with MS.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by educational grants from Biogen MA, Inc., Bristol-Myers Squibb Company, EMD Serono, Inc., and Sanofi Genzyme.
Neurologists, PAs, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Racke reports he is a consultant for Teva Neuroscience, Inc.
Dr. Cross reports that she receives research support from The Conrad N. Hilton Foundation; and U.S. Department of Defense. She is on the advisory committee for EMD Serono, Inc.; and Genentech, Inc./Roche. She is a consultant for Biogen; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc./Roche; and Novartis.
Dr. Williams reports that she receives research support from EMD Serono, Inc.; Genentech, Inc.; and Novartis. She serves on the advisory committee for AbbVie Inc.; Biogen Idec; Bristol-Myers Squibb Company; EMD Serono, Inc.; Genentech, Inc.; Novartis; and Sanofi Genzyme. She serves as a consultant for AbbVie Inc.; Biogen Idec; Bristol-Myers Squibb Company; EMD Serono, Inc.; Genentech, Inc.; Novartis; and Sanofi Genzyme.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-100-H01-P.
Call us at 877.CME.PROS (877.263.7767).